Anti-HAMP ADCC Enhanced Antibody (LY2787106) is an ADCC enhanced antibody produced by our Afuco™ platform. This is a fully humanized antibody againsts hepcidin currently in phase I human trials for cancer-related anemia.
Figure 1 Percent change in hemoglobin level from baseline to end of cycle 4 (week 12).
Values shown are for evaluable patients in study part B who received 10 mg/kg LY2787106 weekly (QW) without and with oral iron (cohorts B1 [n = 6] and B2 [n = 7], respectively). Only patients with a baseline and postbaseline result are included; for patients who did not reach week 12, their final assessment was used
Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.
Figure 2 LY2787106 concentration-versus-time profile (a) and clearance-versus-dose scatter plot (b)
Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.
Figure 3 Change in serum iron level (expressed as ratio relative to baseline) versus time course following (a) a single dose and (b) multiple weekly doses (after 5th dose).
Relative_Nominal_Time (h) is the protocol-scheduled time after last dose in hours presented on a log scale for greater clarity and better presentation of the earlier time point, where 168 h = 7 days = 1 week and 336 h = 14 days = 2 weeks. Data are displayed as mean ± SD
Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.
Figure 4 Change in ferritin level (expressed as ratio relative to baseline) versus time course following (a) a single dose and (b) multiple weekly doses (after 5th dose).
Relative_Nominal_Time (hr) is the protocol-scheduled time after last dose in hours presented on a log scale for greater clarity and better presentation of the earlier time point, where 168 h = 7 days = 1 week and 336 h = 14 days = 2 weeks. Data are displayed as mean ± SD
Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.
Figure 5 Transferrin saturation (percentage) concentration-versus-time profile following (a) a single dose and (b) multiple weekly doses (after 5th dose).
Relative_Nominal_Time (hr) is the protocol-scheduled time after last dose in hours presented on a log scale for greater clarity and better presentation of the earlier time point, where 168 h = 7 days = 1 week and 336 h = 14 days = 2 weeks. Data are displayed as mean ± SD
Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.
Figure 6 Hepcidin (ng/mL) concentration-versus-time profile following (a) a single dose and (b) multiple weekly doses (after 5th dose).
Relative_Nominal_Time (hr) is the protocol-scheduled time after last dose in hours presented on a log scale for greater clarity and better presentation of the earlier time point, where 168 h = 7 days = 1 week and 336 h = 14 days = 2 weeks. Data are displayed as mean ± SD
Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-430 | Recombinant Anti-human HAMP Antibody | WB, IP, FuncS | IgG |
MHH-430 | Recombinant Human Anti-human HAMP Antibody | ELISA, WB, IP, FuncS | IgG |
HPAB-0226-YC | Mouse Anti-HAMP Recombinant Antibody (HPAB-0226-YC) | ELISA, Neut, SPR, FuncS | Mouse IgG |
HPAB-0227-YC | Rat Anti-HAMP Recombinant Antibody (HPAB-0227-YC) | ELISA | Rat IgG |
HPAB-0915-WJ | Mouse Anti-HAMP Recombinant Antibody (HPAB-0915-WJ) | Inhib | Mouse IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-430-S(P) | Recombinant Anti-human HAMP Antibody scFv Fragment | FC, RIA, Biosensors, FuncS | scFv |
MHH-430-S(P) | Recombinant Human Anti-human HAMP Antibody scFv Fragment | ELISA, WB, IF, FuncS | scFv |
HPAB-0226-YC-S(P) | Mouse Anti-HAMP Recombinant Antibody; scFv Fragment (HPAB-0226-YC-S(P)) | ELISA, Neut | Mouse scFv |
HPAB-0227-YC-S(P) | Rat Anti-HAMP Recombinant Antibody; scFv Fragment (HPAB-0227-YC-S(P)) | ELISA | Rat scFv |
HPAB-0915-WJ-S(P) | Mouse Anti-HAMP Recombinant Antibody; scFv Fragment (HPAB-0915-WJ-S(P)) | ELISA | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
MHH-430-F(E) | Recombinant Human Anti-human HAMP Antibody Fab Fragment | WB, FuncS | Fab |
HPAB-0226-YC-F(E) | Mouse Anti-HAMP Recombinant Antibody; Fab Fragment (HPAB-0226-YC-F(E)) | ELISA, Neut | Mouse Fab |
HPAB-0227-YC-F(E) | Rat Anti-HAMP Recombinant Antibody; Fab Fragment (HPAB-0227-YC-F(E)) | ELISA | Rat Fab |
HPAB-0228-YC-F(E) | Human Anti-HAMP Recombinant Antibody; Fab Fragment (HPAB-0228-YC-F(E)) | ELISA, FuncS | Human Fab |
HPAB-0915-WJ-F(E) | Mouse Anti-HAMP Recombinant Antibody; Fab Fragment (HPAB-0915-WJ-F(E)) | ELISA | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-338CL | Human Anti-HAMP Recombinant Antibody (TAB-338CL) | ELISA | Human IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0306CL-S(P) | Mouse Anti-HAMP Recombinant Antibody; scFv Fragment (TAB-0306CL-S(P)) | ELISA, Neut, FC, Ferritin assay, FuncS | Mouse scFv |
TAB-0307CL-S(P) | Mouse Anti-HAMP Recombinant Antibody; scFv Fragment (TAB-0307CL-S(P)) | ELISA, Neut, FC, Ferritin assay, FuncS | Mouse scFv |
TAB-0308CL-S(P) | Mouse Anti-HAMP Recombinant Antibody; scFv Fragment (TAB-0308CL-S(P)) | ELISA, Neut, FC, Ferritin assay, FuncS | Mouse scFv |
TAB-0309CL-S(P) | Mouse Anti-HAMP Recombinant Antibody; scFv Fragment (TAB-0309CL-S(P)) | ELISA, Neut, FC, Ferritin assay, FuncS | Mouse scFv |
TAB-0306CL-F(E) | Mouse Anti-HAMP Recombinant Antibody; Fab Fragment (TAB-0306CL-F(E)) | ELISA, Neut, FC, Ferritin assay, FuncS | Chimeric (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
PABX-080 | Recombinant Human Anti-Hepcidin Antibody | WB, ELISA, FuncS | IgG |
PABX-080-S (P) | Recombinant Human Anti-Hepcidin Antibody scFv Fragment | WB, ELISA, FuncS | scFv |
PABX-080-F (E) | Recombinant Human Anti-Hepcidin Antibody Fab Fragment | WB, ELISA, FuncS | Fab |
There are currently no Customer reviews or questions for AFC-324CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.